Novavax, Inc. (NASDAQ: NVAX) is the latest drug maker to hit a key milestone in the development of a much-needed COVID-19 vaccine. The drug developer has started the late-stage study of its experimental COVID-19 vaccine after delaying trials twice due to scaling problems.
Novavax COVID-19 Vaccine Trials
The drug developer plans to enroll up to 30,000 volunteers across 115 sites in the U.S and Mexico. Two-thirds of the volunteers are to receive the experimental vaccine shot 21-days apart, with the rest being placed under placebo treatment.
In addition to U.S and Mexico trials, Novavax is also running fully-enrolled Phase 2b trials in South Africa and Phase ½ continuation in Australia, and the U.S. Efficacy results from the trials should be made available early in the year.
While the company lags behind on the development of the vaccine, experts maintain that more than one vaccine is needed to combat the deadly virus, which is causing havoc worldwide. Currently, only Pfizer Inc.(NYSE: PFE) and Moderna Inc. (NASDAQ: MRNA) COVID-19 vaccines have obtained regulatory approval.
COVID-19 Vaccine Supplies
With the pandemic killing thousands of people daily, there is a need for more cost-effective vaccines to help bring the pandemic under control. Even though Novavax is in the late-stage of trials, it has already signed supply agreements with several countries.
Governments worldwide have resorted to signing agreements in advance in a bid to secure supplies to combat the virus. Currently, the U.S leads the pack in signing COVID-19 vaccine supply agreements with the major drug makers.
The U.K has signed a deal that guarantees it 60 million doses of the Novavax vaccine once it is made available. Novavax also intends to supply up to 100 million doses to the U.S, having secured $1.6 billion in financing from the government for the development of the vaccine.
Novavax has been on an impressive run in 2020, rallying by more than 300%. While the stock has pulled lower in recent months, it is still up for the year and looking increasingly bullish.